Form 4: Cogent Biosciences Director Arlene Morris Acquires Stock Options
SEC Form 4
Director Arlene Morris acquired 44,700 stock options in Cogent Biosciences, Inc. on June 5, 2024.
Summary
- Arlene Morris, a director of Cogent Biosciences, Inc., reported a transaction on June 5, 2024.
- Morris acquired 44,700 stock options with an exercise price of $8.92.
- These options vest fully on the earlier of June 5, 2025, or the date of the 2025 Annual Meeting of Stockholders.
- Following the transaction, Morris directly owns 44,700 derivative securities.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard regulatory filing reporting an insider transaction. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in the biotechnology industry. It provides transparency into the actions of company directors.
Stakeholder Impact
- The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of transaction: Arlene Morris acquired stock options. |
| 06/05/2025 | Stock options vest on the earlier of this date or the date of the 2025 Annual Meeting of Stockholders. |
| 06/13/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.